Non-PVC IV Bags Market Growing at 9.8% CAGR; North America Leads with 38% Share; Key Players: Baxter, B. Braun, RENOLIT, Pfizer

The Global Non-PVC IV Bags Market was valued at USD 2.08 billion in 2024 and is projected to reach USD 4.40 billion by 2032, growing at a CAGR of 9.8 percent during the forecast period. These IV bags are made from materials such as polypropylene, polyethylene, copolyester-ether, and ethylene-vinyl acetate (EVA) and are used in intravenous therapy, parenteral nutrition, chemotherapy, blood transfusion, fluid and electrolyte administration, and other medical applications. Demand is rising due to increasing emphasis on patient safety, stricter regulations on PVC packaging (especially those containing DEHP plasticizers), and growing global healthcare needs including chronic disease management and rise in hospital admissions.

Market growth is also supported by adoption of single-chamber and multi-chamber bag formats tailored for different therapies, increasing use in hospitals and ambulatory care centers, and rising demand in regions with expanding healthcare infrastructure. North America currently holds the largest share due to strong regulatory frameworks and advanced medical standards, while Asia-Pacific is emerging as the fastest-growing region driven by rising patient volumes, increasing healthcare spending, and ongoing modernization of hospitals and infusion therapy services.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/non-pvc-iv-bags-market?sai-v

The Non-PVC IV Bags Market is growing rapidly with safer, eco-friendly infusion solutions that reduce chemical leaching and enhance patient care across healthcare settings.

Key Developments

United States
✅ October 2025: U.S. hospitals expanded adoption of DEHP-free and non-PVC multi-chamber IV bags to improve medication safety and meet stricter environmental and patient-care regulations.

✅ August 2025: American medical device manufacturers introduced next-generation polypropylene and EVA-based IV bags designed for high-stability biologics and oncology medications.

✅ May 2025: U.S. pharma outsourcing facilities integrated automated sterile filling technologies for non-PVC IV bags to scale production for parenteral nutrition and hydration therapy.

Japan
✅ September 2025: Japanese healthcare providers accelerated use of eco-friendly non-PVC infusion bags to reduce chemical leaching risks and comply with evolving hospital sustainability mandates.

✅ June 2025: Japan's medical device innovators launched advanced multilayer non-PVC IV bags with superior vapor and oxygen barrier properties for sensitive injectable drugs.

✅ March 2025: Japanese research institutions developed next-gen metallocene-based non-PVC polymers to improve flexibility, durability, and sterilization compatibility for IV bag manufacturing.

Mergers & Acquisitions

United States
✅ July 2025: A major U.S. medical packaging company acquired a non-PVC infusion systems startup to expand its portfolio in sterile parenteral delivery solutions.

Japan
✅ February 2025: A Japanese IV therapy manufacturer partnered with a domestic polymer science company to co-develop high-performance non-PVC materials for next-gen infusion bags.

✅ January 2025: A Japan-based medical device supplier formed a strategic alliance with a U.S. distributor to expand international availability of premium non-PVC IV bag solutions.

Key Players
Baxter | Angiplast Pvt. Ltd. | PolyCine GmbH | RENOLIT | Kraton Corp. | B. Braun Melsungen AG | Pfizer, Inc. | Shanghai Xin Gen Eco-Technologies Co., Ltd.

Key Highlights
• Baxter - Holds 18.6% share of the global non-PVC IV bags market, driven by its broad parenteral solutions portfolio, advanced IV container technologies, and global hospital network penetration.

• Angiplast Pvt. Ltd. - Accounts for 6.9% market share, supported by its wide range of medical disposables, cost-effective non-PVC IV bag manufacturing, and strong presence in emerging markets.

• PolyCine GmbH - Maintains 7.4% share, known for its high-quality polypropylene and multilayer film solutions designed for non-PVC medical bags and pharmaceutical packaging.

• RENOLIT - Holds 10.3% share, driven by its strong expertise in medical-grade polymer films and global supply partnerships with IV bag manufacturers.

• Kraton Corp. - Represents 5.8% share, supported by its advanced styrenic block copolymers (SBCs) used in developing safe, flexible, and eco-friendly non-PVC IV bags.

• B. Braun Melsungen AG - Accounts for 16.1% share, backed by its extensive IV therapy product line, PVC-free infusion bag innovations, and significant hospital market presence.

• Pfizer, Inc. - Maintains 8.7% share, driven by its injectable drug portfolio that increasingly adopts non-PVC IV bags for enhanced safety and compatibility.

• Shanghai Xin Gen Eco-Technologies Co., Ltd. - Holds 4.9% share, recognized for its cost-efficient, environmentally friendly IV bag materials and growing footprint in Asia-Pacific healthcare markets.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=non-pvc-iv-bags-market?sai-v

Market Drivers

Growing shift away from PVC-based medical products due to concerns over DEHP toxicity and chemical leaching.

Rising adoption of eco-friendly, biocompatible, and safer IV packaging materials across hospitals and clinics.

Increasing prevalence of chronic diseases leading to higher demand for IV administration of medications and fluids.

Rapid growth of parenteral nutrition therapies, chemotherapy, and emergency care requiring safe infusion systems.

Regulatory support promoting the use of non-PVC and non-DEHP medical devices to improve patient safety.

Advancements in non-PVC materials such as polypropylene (PP), polyethylene (PE), ethylene vinyl acetate (EVA), and multilayer composites.

Expanding usage of multi-chamber non-PVC IV bags for complex drug formulations and extended shelf life.

Rising investments by pharmaceutical manufacturers in sterile, contamination-resistant IV packaging technologies.

Industry Developments

Launch of advanced multilayer non-PVC bag technologies offering improved durability, drug compatibility, and heat resistance.

Growing production of EVA and PP-based IV bags for chemotherapy drugs, antibiotics, and parenteral nutrition.

Expansion of manufacturing facilities by global players to meet rising demand for DEHP-free medical packaging.

Development of innovative multi-chamber IV bags enabling on-demand mixing of drug components.

Increased adoption of non-PVC bags in oncology due to reduced drug adsorption and improved safety.

Partnerships between pharma companies and packaging manufacturers for customized sterile IV bag solutions.

Strengthening of regulatory norms in the U.S., Europe, and Asia favoring non-PVC, non-toxic IV solutions.

Regional Insights

North America - 38%: Driven by strong regulatory pressure to eliminate DEHP, advanced hospital infrastructure, and widespread adoption of non-PVC infusion systems.

Europe - 30%: Supported by strict environmental and patient safety regulations and increasing demand for DEHP-free medical packaging.

Asia Pacific - 25%: Fueled by rising healthcare investments, expanding hospital capacity, and growing pharma manufacturing in India, China, and Japan.

Latin America - 4%: Driven by increasing hospital modernization and gradual shift toward safer IV administration products.

Middle East & Africa - 3%: Supported by expanding healthcare infrastructure and rising focus on safe infusion therapies.

Key Segments:

➥ By Type
Single-chambered IV bags dominate the market due to their widespread use in standard fluid therapy, medication delivery, and electrolyte solutions. They are preferred for routine hospital applications because of their simplicity, safety, and cost-effectiveness.
Multi-chambered IV bags are gaining traction for their ability to store incompatible components separately, allowing mixing just before administration-ideal for parenteral nutrition, specialty medications, and customized therapies.

➥ By Material
Polyethylene (PE) IV bags are widely used for their durability, flexibility, and compatibility with a broad range of pharmaceutical solutions.
Polypropylene (PP) IV bags offer high heat resistance and are preferred for sterilization-intensive applications, making them suitable for advanced drug formulations.
Ethylene-vinyl acetate (EVA) IV bags are well-suited for frozen storage, parenteral nutrition, and sensitive biologics due to their excellent low-temperature performance and chemical stability.
Others include emerging polymer blends and specialty materials designed for enhanced barrier properties, eco-friendliness, and improved drug compatibility.

➥ By Content
Frozen mixtures are typically used for long-term storage of nutrition solutions, biologics, and temperature-sensitive formulations, ensuring stability until thawed for use.
Liquid mixtures remain the most common form in hospitals and clinics, used for immediate administration of hydration fluids, drug solutions, and electrolyte formulations.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/non-pvc-iv-bags-market?sai-v
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.